

XAVIER BECERRA
Attorney General of California
MATTHEW M. DAVIS
Supervising Deputy Attorney General
GIOVANNI F. MEJIA
Deputy Attorney General
State Bar No. 309951
600 West Broadway, Suite 1800
San Diego, CA 92101
P.O. Box 85266
San Diego, CA 92186-5266
Telephone: (619) 738-9072
Facsimile: (619) 645-2061

Attorneys for Complainant

FILED
STATE OF CALIFORNIA
MEDICAL BOARD OF CALIFORNIA
SACRAMENTO DEC 31 20 18
BY SARA GASTON ANALYST

BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

Case No. 800-2017-031603

Mark Scheier, M.D.
5451 La Palma Avenue, Ste. 22
La Palma, CA 90623

ACCUSATION

**Physician's and Surgeon's Certificate
No. A 36345,**

Respondent.

Complainant alleges:

PARTIES

1. Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official capacity as the Executive Director of the Medical Board of California, Department of Consumer Affairs ("Board").

2. On or about February 23, 1981, the Medical Board issued Physician's and Surgeon's Certificate No. A 36345 to Respondent Mark Scheier, M.D. ("Respondent"). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought herein and will expire on May 31, 2020, unless renewed.

///

JURISDICTION

3. This Accusation is brought before the Board, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.

4. Section 2227 of the Code states:

“(a) A licensee whose matter has been heard by an administrative law judge of the Medical Quality Hearing Panel as designated in Section 11371 of the Government Code, or whose default has been entered, and who is found guilty, or who has entered into a stipulation for disciplinary action with the board, may, in accordance with the provisions of this chapter:

“(1) Have his or her license revoked upon order of the board.

“(2) Have his or her right to practice suspended for a period not to exceed one year upon order of the board.

“(3) Be placed on probation and be required to pay the costs of probation monitoring upon order of the board.

“(4) Be publicly reprimanded by the board. The public reprimand may include a requirement that the licensee complete relevant educational courses approved by the board.

“(5) Have any other action taken in relation to discipline as part of an order of probation, as the board or an administrative law judge may deem proper.

“(b) Any matter heard pursuant to subdivision (a), except for warning letters, medical review or advisory conferences, professional competency examinations, continuing education activities, and cost reimbursement associated therewith that are agreed to with the board and successfully completed by the licensee, or other matters made confidential or privileged by existing law, is deemed public, and shall be made available to the public by the board pursuant to Section 803.1.”

/ / / /

/ / / /

/ / / /

/ / / /

1 5. Section 2234 of the Code states, in pertinent part:

2 “The board shall take action against any licensee who is charged with unprofessional
3 conduct. In addition to other provisions of this article, unprofessional conduct includes, but
4 is not limited to, the following:

5 “(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting
6 the violation of, or conspiring to violate any provision of this chapter.

7 “(b) Gross negligence.

8 “(c) Repeated negligent acts. To be repeated, there must be two or more negligent
9 acts or omissions. An initial negligent act or omission followed by a separate and distinct
10 departure from the applicable standard of care shall constitute repeated negligent acts.

11 “(1) An initial negligent diagnosis followed by an act or omission medically
12 appropriate for that negligent diagnosis of the patient shall constitute a single negligent act.

13 “(2) When the standard of care requires a change in the diagnosis, act, or omission
14 that constitutes the negligent act described in paragraph (1), including, but not limited to, a
15 reevaluation of the diagnosis or a change in treatment, and the licensee’s conduct departs
16 from the applicable standard of care, each departure constitutes a separate and distinct
17 breach of the standard of care.

18 “....”

19 6. Section 2242 of the Code states, in pertinent part:

20 “(a) Prescribing, dispensing, or furnishing dangerous drugs as defined in
21 Section 4022 without an appropriate prior examination and a medical indication, constitutes
22 unprofessional conduct.

23 “....”

24 7. Section 2266 of the Code states: “The failure of a physician and surgeon to maintain
25 adequate and accurate records relating to the provision of services to their patients constitutes
26 unprofessional conduct.”

27 / / / /

28 / / / /

1 8. Section 725 of the Code states, in pertinent part:

2 “(a) Repeated acts of clearly excessive prescribing, furnishing, dispensing, or
3 administering of drugs or treatment, repeated acts of clearly excessive use of
4 diagnostic procedures, or repeated acts of clearly excessive use of diagnostic or
5 treatment facilities as determined by the standard of the community of licensees is
6 unprofessional conduct for a physician and surgeon, dentist, podiatrist,
7 psychologist, physical therapist, chiropractor, optometrist, speech-language
8 pathologist, or audiologist.

9 “(b) Any person who engages in repeated acts of clearly excessive
10 prescribing or administering of drugs or treatment is guilty of a misdemeanor and
11 shall be punished by a fine of not less than one hundred dollars (\$100) nor more
12 than six hundred dollars (\$600), or by imprisonment for a term of not less than 60
13 days nor more than 180 days, or by both that fine and imprisonment.

14 “....”

15 **FIRST CAUSE FOR DISCIPLINE**

16 **(Gross Negligence)**

17 9. Respondent has subjected his Physician’s and Surgeon’s Certificate No. A 36345 to
18 disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (b), of
19 the Code in that he committed gross negligence in his care and treatment of one or more patients,
20 as more particularly alleged hereinafter:

21 **Patient A**

22 10. On or about December 11, 2011,¹ a then forty-three-year-old male, “patient A”,² was
23 admitted to a hospital in or around La Palma, California by Respondent. At the time, Respondent
24 documented complaints of chest pain, shortness of breath and weakness. Respondent also

25 ¹ Any medical care or treatment rendered by Respondent more than seven years prior to
26 the filing of the instant Accusation is described for informational purposes only and not pleaded
as a basis for disciplinary action.

27 ² Patients’ true names are not used in the instant Accusation to maintain patient
28 confidentiality. The patients’ identities are known to Respondent or will be disclosed to
Respondent upon receipt of a duly issued request for discovery and in accordance with
Government Code section 11507.6.

1 documented a long history of chronic neck pain following a fall several years prior, that patient A
2 had a neurostimulator in place and that patient A was on "high-dose pain medications along with
3 [sic] muscle relaxant for relief of his pain." During patient A's December 2011 hospital stay, on
4 or about December 13, 2011, an imaging study of patient A's cervical spine found "[v]ery mild
5 degenerative changes of the cervical spine." Eventually, patient A was diagnosed with
6 pancreatitis, his condition improved and he was discharged home on or about December 14, 2011.
7 In his discharge note, Respondent documented that patient A was to "[f]ollow up with [sic] pain
8 doctor in one week."

9 11. Subsequent to patient A's December 2011 hospitalization, Respondent had
10 approximately 25 office visits with patient A through as late as April 2013. Throughout this
11 period, Respondent prescribed multiple opioids and multiple benzodiazepines to patient A in
12 unsafe, at times excessive, combinations and dosages.

13 12. Beginning on or about January 2, 2012, the California Controlled Substance
14 Utilization Review and Evaluation System ("CURES") database lists concurrent prescriptions for
15 multiple opioid analgesics (Demerol³ and hydromorphone⁴) and a benzodiazepine (clonazepam⁵)
16 as having been issued by Respondent and filled to patient A:

| Date Filled | Drug Name | Strength | Qty | Days Supply |
|-------------|-----------------------|-------------|-----|-------------|
| 01/02/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 01/02/12 | Clonazepam | 2 mg | 90 | 30 |
| 01/02/12 | Hydromorphone HCL | 8 mg | 150 | 25 |
| 01/23/12 | Hydromorphone HCL | 8 mg | 150 | 25 |
| 01/30/12 | Clonazepam | 2 mg | 90 | 30 |
| 02/10/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |

24 ³ Demerol is a brand name for meperidine, a Schedule II controlled substance pursuant to
25 Health and Safety Code section 11056, subdivision (c), and a dangerous drug pursuant to
Business and Professions Code section 4022.

26 ⁴ Hydromorphone, also known as Dilaudid, is a Schedule II controlled substance pursuant
to Health and Safety Code section 11055, subdivision (b), and a dangerous drug pursuant to
27 Business and Professions Code section 4022.

28 ⁵ Clonazepam is a Schedule IV controlled substance pursuant to Health and Safety Code
section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code
section 4022. It is an anti-anxiety medication in the benzodiazepine family.

| Date Filled | Drug Name | Strength | Qty | Days Supply |
|--------------------|-----------------------|-----------------|------------|--------------------|
| 02/13/12 | Hydromorphone HCL | 8 mg | 150 | 25 |
| 02/21/12 | Clonazepam | 2 mg | 90 | 30 |
| 03/07/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 03/07/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 03/09/12 | Clonazepam | 2 mg | 90 | 30 |

13. The use of opioids in combination with benzodiazepines carries increased risk for adverse events including, but not limited to, respiratory suppression and drug overdose intoxication.

14. Prior to concurrently prescribing multiple opioids and one or more benzodiazepines to Respondent in or around January 2012, or thereafter, Respondent failed to adequately conduct or document an evaluation of patient A.

15. Beginning on or about March 30, 2012 and through on or about September 20, 2012, the CURES database lists a recurring prescription for an additional benzodiazepine, lorazepam,⁶ in addition to continuing prescriptions for Demerol, hydromorphone and clonazepam, as having been issued by Respondent and filled to patient A:

| Date Filled | Drug Name | Strength | Qty | Days Supply |
|--------------------|-----------------------|-----------------|------------|--------------------|
| 03/30/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 03/30/12 | Lorazepam | 2 mg | 60 | 20 |
| 03/30/12 | Clonazepam | 2 mg | 90 | 30 |
| 03/30/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 04/24/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 04/24/12 | Lorazepam | 2 mg | 60 | 20 |
| 04/24/12 | Clonazepam | 2 mg | 90 | 30 |
| 04/24/12 | Hydromorphone HCL | 8 mg | 150 | 25 |
| 05/18/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 05/18/12 | Lorazepam | 2 mg | 90 | 30 |

⁶ Lorazepam is a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.

| | Date Filled | Drug Name | Strength | Qty | Days Supply |
|----|--------------------|-----------------------|-----------------|------------|--------------------|
| 1 | | | | | |
| 2 | 05/18/12 | Clonazepam | 2 mg | 90 | 30 |
| 3 | 05/18/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 4 | 06/04/12 | Suboxone ⁷ | 8 mg-2 mg | 90 | 30 |
| 5 | 06/13/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 6 | 06/13/12 | Clonazepam | 2 mg | 90 | 30 |
| 7 | 06/13/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 8 | 07/10/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 9 | 07/10/12 | Lorazepam | 2 mg | 90 | 30 |
| 10 | 07/10/12 | Clonazepam | 2 mg | 90 | 30 |
| 11 | 07/10/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 12 | 08/03/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 13 | 08/03/12 | Clonazepam | 2 mg | 90 | 30 |
| 14 | 08/03/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 15 | 08/27/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 16 | 08/27/12 | Lorazepam | 2 mg | 90 | 30 |
| 17 | 08/27/12 | Clonazepam | 2 mg | 90 | 30 |
| 18 | 08/27/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 19 | 09/20/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 20 | 09/20/12 | Lorazepam | 2 mg | 90 | 30 |
| 21 | 09/20/12 | Clonazepam | 2 mg | 90 | 30 |
| 22 | 09/20/12 | Hydromorphone HCL | 8 mg | 150 | 30 |

16. Respondent failed to adequately establish or document a medical indication or rationale for prescribing lorazepam to patient A, independently or concurrently with other opioid or benzodiazepine medications, in or around March 2012 or thereafter.

/// /

/// /

/// /

⁷ Suboxone is a brand name for buprenorphine and naloxone, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous drug pursuant to Business and Professions Code section 4022.

17. The CURES database also lists a one-time Suboxone prescription issued by Respondent and filled to patient A on or about June 4, 2012. Respondent failed to adequately establish or document a medical indication or rationale for prescribing Suboxone to patient A.

18. Beginning in or around October 2012, through in or around April 2013, the CURES database lists, at various times, prescriptions for additional opioid analgesics (Opana⁸ and fentanyl⁹) and an additional benzodiazepine (alprazolam¹⁰), as having been issued by Respondent and filled to patient A in addition to continuing prescriptions for Demerol, hydromorphone and clonazepam:

| Date Filled | Drug Name | Strength | Qty | Days Supply |
|-------------|-----------------------|-------------|-----|-------------|
| 10/12/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 10/12/12 | Clonazepam | 2 mg | 90 | 30 |
| 10/12/12 | Alprazolam | 2 mg | 90 | 30 |
| 10/12/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 10/30/12 | Opana ER | 40 mg | 60 | 30 |
| 11/02/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 11/02/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 11/03/12 | Alprazolam | 2 mg | 90 | 30 |
| 11/03/12 | Clonazepam | 2 mg | 90 | 30 |
| 11/23/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 11/23/12 | Clonazepam | 2 mg | 90 | 30 |
| 11/23/12 | Alprazolam | 2 mg | 90 | 30 |
| 11/23/12 | Opana ER | 40 mg | 60 | 30 |
| 11/23/12 | Hydromorphone HCL | 8 mg | 150 | 25 |

⁸ Opana is a brand name for oxymorphone hydrochloride, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b), and a dangerous drug pursuant to Business and Professions Code section 4022.

⁹ Fentanyl is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (c), and a dangerous drug pursuant to Business and Professions Code section 4022.

¹⁰ Alprazolam, also known as Xanax, is in the benzodiazepine family of drugs, a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.

| | Date Filled | Drug Name | Strength | Qty | Days Supply |
|----|--------------------|-----------------------------|-----------------|------------|--------------------|
| 1 | | | | | |
| 2 | 12/14/12 | Lorazepam | 2 mg | 90 | 30 |
| 3 | 12/14/12 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 4 | 12/17/12 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 5 | 12/17/12 | Alprazolam | 2 mg | 90 | 30 |
| 6 | 12/17/12 | Opana ER | 40 mg | 60 | 30 |
| 7 | 12/31/12 | Clonazepam | 2 mg | 90 | 30 |
| 8 | 01/09/13 | Alprazolam | 2 mg | 90 | 30 |
| 9 | 01/11/13 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 10 | 01/11/13 | Clonazepam | 1 mg | 90 | 30 |
| 11 | 01/11/13 | Alprazolam | 2 mg | 90 | 30 |
| 12 | 01/11/13 | Fentanyl Transdermal System | 100 mcg/hr | 10 | 30 |
| 13 | 01/11/13 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 14 | 02/04/13 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 15 | 02/04/13 | Clonazepam | 2 mg | 90 | 30 |
| 16 | 02/04/13 | Fentanyl Transdermal System | 100 mcg/hr | 10 | 30 |
| 17 | 02/04/13 | Alprazolam | 2 mg | 90 | 30 |
| 18 | 02/04/13 | Hydromorphone HCL | 8 mg | 150 | 30 |
| 19 | 02/22/13 | Hydromorphone HCL | 8 mg | 150 | 25 |
| 20 | 02/26/13 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 21 | 02/26/13 | Fentanyl Transdermal System | 100 mcg/hr | 10 | 30 |
| 22 | 03/01/13 | Alprazolam | 2 mg | 90 | 30 |
| 23 | 03/01/13 | Clonazepam | 2 mg | 90 | 30 |
| 24 | 03/22/13 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 30 |
| 25 | 03/22/13 | Alprazolam | 2 mg | 90 | 30 |
| 26 | 03/22/13 | Fentanyl Transdermal System | 100 mcg/hr | 10 | 30 |
| 27 | 03/22/13 | Hydromorphone HCL | 8 mg | 150 | 25 |
| 28 | 03/25/13 | Clonazepam | 2 mg | 90 | 30 |
| | 04/12/13 | Demerol Hydrochloride | 100 mg-1 ml | 150 | 26 |

| | Date Filled | Drug Name | Strength | Qty | Days Supply |
|---|--------------------|-------------------|-----------------|------------|--------------------|
| 1 | | | | | |
| 2 | 04/12/13 | Clonazepam | 2 mg | 90 | 30 |
| 3 | 04/12/13 | Alprazolam | 2 mg | 90 | 30 |
| 4 | 04/12/13 | Hydromorphone HCL | 8 mg | 150 | 25 |

19. Throughout the period in or around October 2012 to April 2013, Respondent failed to adequately establish or document a medical indication or rationale for changes to the opioids or benzodiazepines prescribed to patient A.

20. On or about April 12, 2013, patient A was found dead at his home. Patient A's cause of death was listed as "[a]cute polydrug intoxication" due to "[c]ombined effects of meperidine/norimeperidine, alprazolam/hydroxylalprazolam and hydromorphone[.]"

21. Throughout the course of Respondent's care and treatment of patient A, Respondent failed to review the CURES database for controlled substance prescriptions listed for patient A.

22. On multiple occasions throughout the course of Respondent's care and treatment of patient A, Respondent provided a prescription refill to patient A early, based upon the prescription's quantity and intended dosage.

23. Although Respondent's medical record for patient A documents multiple indicia that patient A suffered from psychological or psychiatric problems, Respondent failed to adequately coordinate or attempt to coordinate patient A's care and treatment with any mental health provider, or refer patient A to a psychiatrist.

24. On multiple occasions throughout the course of Respondent's treatment of patient A, a note for an office visit between Respondent and patient A contained content that failed to adequately or accurately describe observations or conduct occurring on the date indicated in the note, but rather was generated by default by the medical-record-keeping system used by Respondent or was copied forward from one or more prior office visit notes.

25. On multiple occasions throughout the course of Respondent's treatment of patient A, an office visit note authored by Respondent for patient A failed to adequately and accurately document one or more medications or medication amounts prescribed by Respondent to patient A.

1 26. Respondent committed gross negligence in his care and treatment of patient A in that
2 he prescribed controlled substances to patient A without a proper evaluation including, but not
3 limited to, failing to adequately:

- 4 (a) establish the nature and extent of patient A's pain;
- 5 (b) establish patient A's history of prior pain treatments;
- 6 (c) establish how patient A would use the various prescribed controlled substances;
- 7 (d) assess the significance of patient A's apparent psychological or psychiatric
8 problems and how they may impact his ability to safely use controlled substances;
- 9 (e) order or review diagnostic testing regarding the potential cause for patient A's
10 reported pain;
- 11 (f) develop a differential diagnosis for patient A's reported pain;
- 12 (g) review the CURES database for controlled substances listed as prescribed to
13 patient A; and
- 14 (h) develop a treatment plan for patient A's reported chronic pain ailment.

15 27. Respondent committed gross negligence in his care and treatment of patient A in that
16 he failed to properly monitor his treatment of patient A with controlled substances including, but
17 not limited to, failing to adequately:

- 18 (a) assess how Respondent's treatment of patient A with various controlled
19 substances was impacting patient A and patient A's functioning;
- 20 (b) monitor controlled substances prescription refills;
- 21 (c) abstain from prescribing multiple controlled substances in unsafe combinations
22 and dosages; and
- 23 (d) collaborate or consult with other medical providers regarding the treatment of
24 patient A.

25 **Patient B**

26 28. On or about September 4, 2013, a then forty-year-old female, "patient B", presented
27 to Respondent for the first time. In his office visit note for this appointment, Respondent
28 documented, among other things, "No Medical History", "no Anxiety [sic]", a diagnosis of lupus,

1 a history of Suboxone use for five years, a history of chronic pain and a back and leg injury, an
2 assessment of opioid dependence in remission, that patient B was going to Narcotics Anonymous
3 meetings and that patient B's family was aware of "old abuse problems." Respondent
4 documented prescribing a thirty-day supply of Suboxone 2 mg-0.5 mg (180 total, to be
5 administered six times daily), with no refills.

6 29. Although Respondent documented an opioid use disorder in the September 4, 2013
7 office visit note, Respondent failed to adequately develop or document a medical history,
8 substance use or abuse history, and social history to corroborate such diagnosis. Respondent also
9 failed to adequately develop or document a treatment plan for the prescribing of Suboxone to
10 patient B.

11 30. Subsequent to September 4, 2013, Respondent documented approximately 52 office
12 visits with patient B through June 27, 2018 (i.e., approximately 53 total visits from September 4,
13 2013 to June 27, 2018).

14 31. On multiple occasions throughout the course of Respondent's care and treatment of
15 patient B, a note for an office visit between Respondent and patient B contained content that
16 failed to adequately or accurately describe observations or conduct occurring on the date
17 indicated in the note, but rather was generated by default by the medical-record-keeping system
18 used by Respondent or was copied forward from one or more prior office visit notes.

19 32. On multiple occasions throughout the course of Respondent's care and treatment of
20 patient B, a note for an office visit between Respondent and patient B contained inconsistent
21 statements relevant to patient B's medical care and treatment including, but not limited to,
22 inconsistent statements regarding controlled substance prescriptions for patient B.

23 / / / /

24 / / / /

25 / / / /

26 / / / /

27 / / / /

28 / / / /

33. The CURES database lists recurring prescriptions for buprenorphine (Suboxone) as having been issued by Respondent and filled by patient B in or around September 2013 to February 2014, as well as concurrent Lunesta¹¹ prescriptions starting in or around November 2013:

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|-----------|-------------|-----|-------------|---------|
| 09/04/13 | Suboxone | 2 mg-0.5 mg | 180 | 30 | 0 |
| 10/16/13 | Suboxone | 2 mg-0.5 mg | 120 | 30 | 0 |
| 11/12/13 | Suboxone | 2 mg-0.5 mg | 120 | 30 | 0 |
| 11/12/13 | Lunesta | 3 mg | 30 | 30 | 0 |
| 12/09/13 | Suboxone | 2 mg-0.5 mg | 120 | 30 | 0 |
| 12/09/13 | Lunesta | 3 mg | 30 | 30 | 1 |
| 01/07/14 | Suboxone | 2 mg-0.5 mg | 120 | 30 | 0 |
| 01/16/14 | Lunesta | 3 mg | 30 | 30 | 2 |
| 02/05/14 | Suboxone | 2 mg-0.5 mg | 120 | 30 | 0 |

34. In or around March 2014 to November 2015, the CURES database lists recurring prescriptions of alprazolam as having been issued by Respondent and filled by patient B, concurrent with continuing prescriptions for Suboxone, at a higher dosage, and Lunesta:

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|------------|-----------|-----|-------------|---------|
| 03/07/14 | Alprazolam | 0.5 mg | 90 | 30 | 0 |
| 03/13/14 | Lunesta | 3 mg | 30 | 30 | 3 |
| 03/13/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 04/08/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 04/10/14 | Alprazolam | 0.5 mg | 90 | 30 | 0 |
| 05/12/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 05/12/14 | Lunesta | 3 mg | 30 | 30 | 0 |
| 05/12/14 | Alprazolam | 0.5 mg | 90 | 30 | 1 |

¹¹ Lunesta is a brand name for eszopiclone, a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022. It is a sedative and is used to treat insomnia.

| | Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|----|--------------------|------------------|-----------------|------------|--------------------|----------------|
| 1 | | | | | | |
| 2 | 06/10/14 | Lunesta | 3 mg | 30 | 30 | 1 |
| 3 | 06/11/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 4 | 06/13/14 | Alprazolam | 0.5 mg | 30 | 10 | 0 |
| 5 | 07/15/14 | Lunesta | 3 mg | 30 | 30 | 0 |
| 6 | 07/17/14 | Alprazolam | 0.5 mg | 90 | 30 | 0 |
| 7 | 07/17/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 8 | 08/13/14 | Lunesta | 3 mg | 30 | 30 | 1 |
| 9 | 08/27/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 10 | 09/02/14 | Alprazolam | 0.5 mg | 90 | 30 | 1 |
| 11 | 10/03/14 | Suboxone | 2 mg-0.5 mg | 120 | 30 | 0 |
| 12 | 10/03/14 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 13 | 10/03/14 | Lunesta | 3 mg | 30 | 30 | 0 |
| 14 | 10/07/14 | Suboxone | 8 mg-2 mg | 120 | 30 | 0 |
| 15 | 10/30/14 | Lunesta | 3 mg | 30 | 30 | 1 |
| 16 | 11/25/14 | Lunesta | 3 mg | 30 | 30 | 2 |
| 17 | 11/25/14 | Alprazolam | 2 mg | 90 | 30 | 1 |
| 18 | 12/31/14 | Lunesta | 3 mg | 30 | 30 | 3 |
| 19 | 02/06/15 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 20 | 02/13/15 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 21 | 02/13/15 | Lunesta | 3 mg | 30 | 30 | 0 |
| 22 | 03/01/15 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 23 | 03/08/15 | Lunesta | 3 mg | 30 | 30 | 1 |
| 24 | 03/17/15 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 25 | 04/11/15 | Alprazolam | 2 mg | 90 | 30 | 1 |
| 26 | 04/11/15 | Lunesta | 3 mg | 30 | 30 | 2 |
| 27 | 04/17/15 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |
| 28 | 05/12/15 | Lunesta | 3 mg | 30 | 30 | 0 |
| | 05/15/15 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |
| | 06/09/15 | Lunesta | 3 mg | 30 | 30 | 1 |
| | 06/16/15 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |

| | Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|----|--------------------|------------------|-----------------|------------|--------------------|----------------|
| 1 | | | | | | |
| 2 | 07/09/15 | Lunesta | 3 mg | 30 | 30 | 2 |
| 3 | 07/13/15 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 4 | 07/21/15 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |
| 5 | 08/24/15 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |
| 6 | 09/21/15 | Lunesta | 3 mg | 30 | 30 | 0 |
| 7 | 09/23/15 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 8 | 10/06/15 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |
| 9 | 10/17/15 | Lunesta | 3 mg | 30 | 30 | 1 |
| 10 | 11/10/15 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 11 | 11/20/15 | Lunesta | 3 mg | 30 | 30 | 0 |

35. In or around December 2015 to as late as March 2017, the CURES database lists recurring prescriptions for carisoprodol¹² as having been issued by Respondent and filled by patient B, concurrent with continuing prescriptions for Suboxone, Lunesta and alprazolam:

| | Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|----|--------------------|------------------|-----------------|------------|--------------------|----------------|
| 14 | | | | | | |
| 15 | 12/11/15 | Carisoprodol | 350 mg | 90 | 30 | 0 |
| 16 | 12/11/15 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 17 | 01/14/16 | Lunesta | 3 mg | 30 | 30 | 0 |
| 18 | 01/14/16 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 19 | 02/02/16 | Carisoprodol | 350 mg | 60 | 30 | 0 |
| 20 | 02/02/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 21 | 02/13/16 | Lunesta | 3 mg | 30 | 30 | 1 |
| 22 | 03/04/16 | Carisoprodol | 350 mg | 90 | 30 | 0 |
| 23 | 03/04/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 24 | 03/12/16 | Lunesta | 3 mg | 30 | 30 | 2 |
| 25 | 03/31/16 | Carisoprodol | 350 mg | 60 | 30 | 0 |
| 26 | 04/11/16 | Lunesta | 3 mg | 30 | 30 | 3 |
| 27 | 04/11/16 | Suboxone | 8 mg-2 mg | 90 | 30 | 0 |

¹² Carisoprodol, a generic for Soma, is a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and is a dangerous drug pursuant to Business and Professions Code section 4022. It is often used to treat muscle spasms.

| | Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|----|--------------------|---------------------------|-----------------|------------|--------------------|----------------|
| 1 | | | | | | |
| 2 | 04/26/16 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 3 | 05/06/16 | Carisoprodol | 350 mg | 90 | 30 | 0 |
| 4 | 05/26/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 5 | 06/01/16 | Lunesta | 3 mg | 30 | 30 | 0 |
| 6 | 06/13/16 | Carisoprodol | 350 mg | 90 | 30 | 0 |
| 7 | 06/24/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 8 | 07/18/16 | Lunesta | 3 mg | 30 | 30 | 0 |
| 9 | 07/25/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 10 | 08/10/16 | Carisoprodol | 350 mg | 90 | 30 | 0 |
| 11 | 08/10/16 | Lunesta | 3 mg | 30 | 30 | 1 |
| 12 | 08/26/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 13 | 09/06/16 | Carisoprodol | 350 mg | 90 | 30 | 1 |
| 14 | 09/06/16 | Lunesta | 3 mg | 30 | 30 | 2 |
| 15 | 09/19/16 | Alprazolam | 2 mg | 90 | 30 | 0 |
| 16 | 09/30/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 17 | 10/03/16 | Lunesta | 3 mg | 30 | 30 | 3 |
| 18 | 10/03/16 | Carisoprodol | 350 mg | 90 | 30 | 2 |
| 19 | 11/08/16 | Carisoprodol | 350 mg | 90 | 30 | 0 |
| 20 | 11/08/16 | Lunesta | 3 mg | 30 | 30 | 0 |
| 21 | 11/08/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 22 | 12/05/16 | Lunesta | 3 mg | 30 | 30 | 0 |
| 23 | 12/09/16 | Carisoprodol | 350 mg | 120 | 30 | 0 |
| 24 | 12/11/16 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 25 | 01/13/17 | Lunesta | 3 mg | 30 | 30 | 1 |
| 26 | 01/23/17 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 27 | 01/24/17 | Carisoprodol | 350 mg | 120 | 30 | 0 |
| 28 | 02/20/17 | Carisoprodol | 350 mg | 120 | 30 | 1 |
| | 02/27/17 | Eszopiclone ¹³ | 3 mg | 30 | 30 | 0 |
| | 03/01/17 | Alprazolam | 2 mg | 90 | 30 | 0 |

¹³ Eszopiclone is a generic for Lunesta.

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|--------------------|------------------|-----------------|------------|--------------------|----------------|
| 03/01/17 | Suboxone | 8 mg-2 mg | 60 | 30 | 0 |
| 03/19/17 | Carisoprodol | 350 mg | 120 | 30 | 2 |

36. Throughout the period during which Respondent prescribed eszopiclone (Lunesta) to patient B, in or around November 2013 to at least March 2017, Respondent failed to adequately establish or document a medical indication or rationale for the prescribing of this drug. In fact, during this period, multiple office visit notes authored by Respondent documented that patient B had “no [i]nsomnia[.]”

37. Further, eszopiclone (Lunesta) is a controlled substance with abuse potential, which can be problematic when prescribed in combination with buprenorphine, as prescribed by Respondent to patient B on multiple occasions from in or around November 2013 to at least March 2017.

38. Throughout the period during which Respondent prescribed alprazolam (Xanax) to patient B, in or around March 2014 to at least March 2017, Respondent failed to adequately establish or document a medical indication for the prescribing of a benzodiazepine, such as alprazolam. In fact, during this period, multiple office visit notes authored by Respondent documented that patient B had “no [a]nxiety[.]”

39. Further, alprazolam (Xanax) is a controlled substance with abuse potential, which is problematic and generally contraindicated when prescribed in combination with buprenorphine (Suboxone), as prescribed by Respondent to patient B on multiple occasions in or around March 2014 to at least March 2017.

40. During the period during which Respondent prescribed carisoprodol (Soma) to patient B, in or around December 2015 to at least March 2017, Respondent failed to adequately establish or document a medical indication for the prescribing of a muscle relaxant, such as carisoprodol.

41. Further, carisoprodol (Soma) is a controlled substance with abuse potential, which is problematic when prescribed in combination with buprenorphine (Suboxone) and alprazolam

(Xanax) due to the potential for adverse interactions between them, as prescribed by Respondent to patient B on one or more occasions from in or around December 2015 to at least March 2017.

42. Throughout the course of Respondent's care and treatment of patient B, he failed to adequately assess or document patient B's progress, if any, toward treatment goals related to Respondent's stated diagnosis of opioid use disorder.

43. In an office visit note dated April 20, 2018, Respondent documented that patient B's "family called and stated that patient having [sic] memory loss and more confusion." The office visit note fails to adequately document an evaluation or examination of patient B in light of the report from her family, or corresponding changes to any treatment plan or medication prescriptions for patient B.

44. Although Respondent first documented an opioid use disorder diagnosis and controlled substance prescription for patient B on or about September 4, 2013, Respondent did not order or review a subsequent toxicology drug screen for patient B until, at the earliest, more than four years later, on or about May 30, 2018.

45. Although Respondent first documented an opioid use disorder diagnosis and controlled substance prescription for patient B on or about September 4, 2013, Respondent's medical records for patient B contain no record of his having reviewed a CURES report for patient B until, at the earliest, May 2018.

46. Respondent committed gross negligence in his care and treatment of patient B in that he failed to properly monitor the prescribing of medication to a patient with an opioid use disorder including, but not limited to:

- (a) generating multiple repetitive treatment notes throughout the course of Respondent's prescribing of controlled substances to patient B with large portions of the content of the notes appearing to have been copied forward from a prior note;
- (b) failing to adequately and accurately document medications, and medication amounts, and medication refills prescribed to patient B;

///

- (c) prescribing a benzodiazepine, such as alprazolam, to patient B in combination with buprenorphine without adequate medical indication for the prescribing of a benzodiazepine;
- (d) prescribing a muscle relaxant, such as carisoprodol, to patient B in combination with buprenorphine and alprazolam without adequate medical indication for the prescribing of a muscle relaxant;
- (e) prescribing eszopiclone (Lunesta) to patient B in combination with buprenorphine without adequate medical indication for the prescribing of eszopiclone;
- (f) failing to adequately follow up on or document the result of one or more laboratory studies or specialist consultations for patient B;
- (g) failing to adequately assess or document patient B's progress with regard to any established treatment goals pertinent to her documented diagnosis of an opioid use disorder;
- (h) failing to adequately confirm patient B's compliance with treatment, or lack thereof; and
- (i) failing to adequately respond to one or more reports of a significant change in patient B's condition.

Patient C

47. On or about August 10, 2015, a then twenty-seven-year-old male, "patient C", presented to Respondent for the first time. In his office visit note for this appointment, Respondent documented, among other things, that patient C had been taking one Suboxone 8 mg-2 mg per day, that patient C previously "was on heroin[,] oxycodone and onrocode [sic][,]" a diagnosis of opioid type dependence, in remission, and issuing a prescription for a thirty-day supply of Suboxone 8 mg-2 mg, to be administered once per day, with two refills.

48. At patient C's initial office visit with Respondent on or about August 10, 2015, Respondent failed to adequately establish or document patient C's substance abuse, mental health and social histories sufficient to properly formulate a diagnosis of an opioid use disorder.

///

Further, Respondent failed to adequately establish or document the nature and extent of patient C's prior abuse of certain drugs.

49. At patient C's initial office visit with Respondent on or about August 10, 2015, Respondent failed to adequately establish or document informed consent for buprenorphine therapy including, but not limited to, discussing or documenting discussion of potential harms of buprenorphine therapy or alternative treatment options for an opioid use disorder.

50. At patient C's initial office visit with Respondent on or about August 10, 2015, Respondent failed to adequately establish or document a treatment plan and objectives for patient C.

51. At or before patient C's initial office visit with Respondent on or about August 10, 2015, Respondent failed to review medical records for patient C by any former medical care providers, order or review a urine drug screen or other toxicology drug screening for patient C, or review the CURES database for any controlled substance prescriptions listed for patient C.

52. Subsequent to the August 10, 2015 appointment, Respondent documented approximately 29 office visits with patient C through as late as May 15, 2018 (i.e., thirty total visits documented from August 10, 2015 to May 15, 2018).

53. The CURES database lists recurring prescriptions for Suboxone, seemingly consistent with a prescribing pattern of Suboxone 8 mg-2 mg once per day, as having been issued by Respondent and filled by patient C in or around August 2015 to March 13, 2016:

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|-----------|-----------|-----|-------------|---------|
| 8/14/15 | Suboxone | 8 mg-2 mg | 30 | 30 | 0 |
| 10/7/15 | Suboxone | 8 mg-2 mg | 2 | 2 | 0 |
| 10/11/15 | Suboxone | 8 mg-2 mg | 1 | 1 | 0 |
| 10/12/15 | Suboxone | 8 mg-2 mg | 15 | 15 | 1 |
| 11/9/15 | Suboxone | 8 mg-2 mg | 1 | 1 | 2 |
| 11/11/15 | Suboxone | 8 mg-2 mg | 11 | 11 | 3 |
| 11/29/15 | Suboxone | 8 mg-2 mg | 7 | 7 | 0 |
| 12/9/15 | Suboxone | 8 mg-2 mg | 1 | 1 | 1 |

| | Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|----|--------------------|------------------|-----------------|------------|--------------------|----------------|
| 1 | | | | | | |
| 2 | 12/10/15 | Suboxone | 8 mg-2 mg | 5 | 5 | 2 |
| 3 | 12/20/15 | Suboxone | 8 mg-2 mg | 4 | 4 | 3 |
| 4 | 12/28/15 | Suboxone | 8 mg-2 mg | 5 | 5 | 0 |
| 5 | 1/10/16 | Suboxone | 8 mg-2 mg | 1 | 1 | 1 |
| 6 | 1/11/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 2 |
| 7 | 1/19/16 | Suboxone | 8 mg-2 mg | 8 | 8 | 3 |
| 8 | 1/25/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 4 |
| 9 | 1/29/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 4 |
| 10 | 2/3/16 | Suboxone | 8 mg-2 mg | 8 | 8 | 0 |
| 11 | 2/8/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 1 |
| 12 | 2/12/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 2 |
| 13 | 2/16/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 3 |
| 14 | 2/20/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 0 |
| 15 | 2/24/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 1 |
| 16 | 2/28/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 2 |
| 17 | 3/3/16 | Suboxone | 8 mg-2 mg | 7 | 7 | 3 |
| 18 | 3/7/16 | Suboxone | 8 mg-2 mg | 6 | 6 | 5 |
| 19 | 3/10/16 | Suboxone | 8 mg-2 mg | 2 | 2 | 4 |
| 20 | 3/11/16 | Suboxone | 8 mg-2 mg | 2 | 2 | 5 |
| 21 | 3/13/16 | Suboxone | 8 mg-2 mg | 1 | 1 | 4 |

20 54. Notes for office visits between Respondent and patient C in or around August 2015 to
21 April 13, 2016 stated on multiple occasions that patient C was “[u]sing smaller amounts” without
22 providing further explanation or identifying the drug or substance purportedly being used in
23 smaller amounts.

24 55. Although Respondent first documented an opioid use disorder diagnosis and opioid
25 prescription for patient C on or about August 14, 2015, Respondent did not order or review a
26 toxicology drug screen for patient C until, at the earliest, approximately eight months later, on or
27 about April 13, 2016.

28 / / / /

56. Respondent would not order or review another toxicology drug screen for patient C until, at the earliest, more than two years later, on or about June 15, 2018.

57. The CURES database lists recurring prescriptions for Suboxone, seemingly consistent with a prescribing pattern of Suboxone 8 mg-2 mg twice per day, as having been issued by Respondent and filled to patient C in or around March 14, 2016 to May 31, 2016:

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|-----------|-----------|-----|-------------|---------|
| 3/14/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 0 |
| 3/19/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 1 |
| 3/24/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 2 |
| 3/29/16 | Suboxone | 8 mg-2 mg | 7 | 3 | 3 |
| 4/2/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 4 |
| 4/8/16 | Suboxone | 8 mg-2 mg | 7 | 3 | 0 |
| 4/11/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 1 |
| 4/15/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 0 |
| 4/20/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 1 |
| 4/25/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 2 |
| 4/30/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 3 |
| 5/6/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 4 |
| 5/12/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 5 |
| 5/17/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 0 |
| 5/22/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 1 |
| 5/26/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 2 |
| 5/31/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 3 |

58. Despite documenting office visits with patient C on March 14, 2016 and April 13, 2016, Respondent did not document any increase in the dosage of patient C's Suboxone prescription until, at the earliest, May 13, 2016. In the office visit note dated May 13, 2016, Respondent failed to adequately establish or document a medical indication or rationale for changing patient C's Suboxone dosage.

59. In the note for the subsequent office visit with patient C dated June 13, 2016, Respondent documented that patient C's current medications included Suboxone 8 mg – 2 mg

once a day, despite documenting in the preceding office visit note, as well as elsewhere in the June 13, 2016 office visit note, that the dosage had been increased to twice a day.

60. Elsewhere in the office visit note dated June 13, 2016, Respondent documented “[d]iscuss change in med [sic]” as a reason for the appointment and the commencement of a prescription for Bunavail¹⁴ 4.2 mg-0.7 mg twice a day.

61. In the note for the subsequent office visit with patient C dated July 13, 2016, Respondent documented that patient C was to stop Bunavail. Further, Respondent again documented inconsistent Suboxone prescription dosages in this office visit note.

62. In or around June and July 2016, Respondent failed to adequately establish or document a medical rationale for starting and stopping patient C on Bunavail.

63. The CURES database lists a prescription for Bunavail as having been issued by Respondent and filled to patient C in or around June 2016, along with prescriptions for Suboxone:

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|-----------|---------------|-----|-------------|---------|
| 6/4/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 4 |
| 6/8/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 5 |
| 6/14/16 | Bunavail | 4.2 mg-0.7 mg | 10 | 5 | 0 |
| 6/17/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 0 |
| 6/20/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 1 |
| 6/25/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 2 |
| 6/30/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 3 |

64. In or around July 2016 to at least March 2017, the CURES database lists no more Bunavail prescriptions, but does list continuing prescriptions for Suboxone as having been issued by Respondent and filled to patient C:

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|-----------|-----------|-----|-------------|---------|
| 7/5/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 4 |
| 7/8/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 5 |

¹⁴ Bunavail is a brand name for a combination of buprenorphine and naloxone, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous drug pursuant to Business and Professions Code section 4022.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

| Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|-------------|-----------|-----------|-----|-------------|---------|
| 7/13/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 7/16/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 1 |
| 7/20/16 | Suboxone | 8 mg-2 mg | 10 | 5 | 2 |
| 7/24/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 3 |
| 7/27/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 4 |
| 7/30/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 5 |
| 8/3/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 6 |
| 8/8/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 8/12/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 8/16/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 1 |
| 8/21/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 2 |
| 8/25/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 3 |
| 8/28/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 4 |
| 9/2/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 5 |
| 9/8/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 9/13/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 1 |
| 9/17/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 2 |
| 9/22/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 3 |
| 9/25/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 4 |
| 9/28/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 5 |
| 10/2/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 6 |
| 10/6/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 10/10/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 1 |
| 10/14/16 | Suboxone | 8 mg-2 mg | 8 | 30 | 2 |
| 10/17/16 | Suboxone | 8 mg-2 mg | 20 | 10 | 3 |
| 10/27/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 4 |
| 11/1/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 11/4/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 5 |
| 11/9/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 0 |
| 11/13/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 1 |

| | Date Filled | Drug Name | Strength | Qty | Days Supply | Refill# |
|----|--------------------|------------------|-----------------|------------|--------------------|----------------|
| 1 | | | | | | |
| 2 | 11/17/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 2 |
| 3 | 11/22/16 | Suboxone | 8 mg-2 mg | 1 | 1 | 3 |
| 4 | 11/23/16 | Suboxone | 8 mg-2 mg | 12 | 6 | 4 |
| 5 | 11/30/16 | Suboxone | 8 mg-2 mg | 2 | 1 | 5 |
| 6 | 12/1/16 | Suboxone | 8 mg-2 mg | 15 | 7 | 0 |
| 7 | 12/9/16 | Suboxone | 8 mg-2 mg | 15 | 5 | 1 |
| 8 | 12/18/16 | Suboxone | 8 mg-2 mg | 15 | 7 | 2 |
| 9 | 12/27/16 | Suboxone | 8 mg-2 mg | 8 | 4 | 3 |
| 10 | 1/2/17 | Suboxone | 8 mg-2 mg | 15 | 7 | 4 |
| 11 | 1/9/17 | Suboxone | 8 mg-2 mg | 15 | 7 | 5 |
| 12 | 1/24/17 | Suboxone | 8 mg-2 mg | 8 | 8 | 7 |
| 13 | 1/29/17 | Suboxone | 8 mg-2 mg | 5 | 2 | 8 |
| 14 | 2/1/17 | Suboxone | 8 mg-2 mg | 15 | 8 | 0 |
| 15 | 2/8/17 | Suboxone | 8 mg-2 mg | 15 | 8 | 1 |
| 16 | 2/16/17 | Suboxone | 8 mg-2 mg | 15 | 8 | 2 |
| 17 | 2/25/17 | Suboxone | 8 mg-2 mg | 7 | 4 | 3 |
| 18 | 3/3/17 | Suboxone | 8 mg-2 mg | 29 | 14 | 0 |
| 19 | 3/23/17 | Suboxone | 8 mg-2 mg | 16 | 8 | 1 |

65. Multiple notes for office visits between Respondent and patient C following June 2016, through at least April 2017, continued to inconsistently document the Suboxone dosages prescribed by Respondent to Patient C.

66. On multiple occasions throughout the course of Respondent's care and treatment of patient C, Respondent failed to adequately assess or document patient C's progress toward any established treatment objectives, patient C's adherence to treatment, or whether patient C was having any adverse effects from his use of buprenorphine (contained in both Suboxone and Bunavail).

67. Although Respondent first documented an opioid use disorder diagnosis and controlled substance prescription for patient C on or about August 14, 2015, Respondent's medical records for patient C contain no record that Respondent reviewed the CURES database

1 for controlled substance prescriptions listed for patient C until, at the earliest, May 2018, almost
2 three years after commencing treatment of the patient.

3 68. Throughout the course of Respondent's care and treatment of patient C through at
4 least May 15, 2018, Respondent failed to adequately ascertain or document the nature or
5 existence of any comorbid illnesses relevant to a patient with an opioid use disorder including,
6 but not limited to, ordering or reviewing laboratory testing to ascertain whether patient C had any
7 liver disease or infectious disease, such as hepatitis or HIV.

8 69. Throughout the course of Respondent's care and treatment of patient C through at
9 least May 15, 2018, Respondent failed to adequately establish or document patient C's
10 involvement in drug abuse counseling or rehabilitation programs.

11 70. Respondent committed gross negligence in his care and treatment of patient C in that
12 he failed to properly evaluate patient C prior to prescribing him medication for treatment of an
13 opioid use disorder including, but not limited to:

- 14 (a) failing to establish sufficient detail regarding patient C's substance abuse history,
15 mental health history, and social history in order to properly establish a diagnosis
16 of an opioid use disorder;
- 17 (b) failing to order or review laboratory testing to ascertain whether patient C had any
18 infection, liver disease, or infectious disease such as hepatitis or HIV;
- 19 (c) failing to adequately establish informed consent at the outset of buprenorphine
20 treatment;
- 21 (d) failing to adequately delineate a treatment plan and objectives for patient C;
- 22 (e) and failing to order or review a toxicology drug screen and the CURES database
23 at the outset of buprenorphine treatment.

24 71. Respondent committed gross negligence in his care and treatment of patient C in that
25 he failed to properly monitor patient C's treatment for an opioid use disorder including, but not
26 limited to:

- 27 (a) failing to adequately document patient C's progress toward any established
28 treatment objectives;

- 1 (b) failing to adequately document patient C's adherence to treatment;
2 (c) failing to adequately document whether patient C suffered any adverse effects
3 from his use of buprenorphine;
4 (d) failing to make adequate efforts to use toxicology drug screens to monitor
5 patient C's compliance with treatment;
6 (e) failing to make adequate efforts to review the CURES database; and
7 (f) failing to adequately establish patient C's involvement in drug abuse counseling
8 or rehabilitation.

9 **SECOND CAUSE FOR DISCIPLINE**

10 **(Repeated Acts of Negligence)**

11 72. Respondent has further subjected his Physician's and Surgeon's Certificate
12 No. A 36345 to disciplinary action under sections 2227 and 2234, as defined by section 2234,
13 subdivision (c), of the Code in that he committed repeated negligent acts in his care and treatment
14 of at least three patients as more particularly alleged hereinafter:

15 73. Paragraphs 9 to 71, above, are hereby incorporated by reference and realleged as if
16 fully set forth herein.

17 74. Respondent committed negligence in his care and treatment of patient A in that he
18 failed to maintain adequate and accurate records pertaining to Respondent's prescribing of
19 controlled substances to patient A for pain including, but not limited to:

- 20 (a) documenting multiple office visit notes with repetitive and inaccurate content that
21 appears to have been entered by default or copied forward from prior notes;
22 (b) failing to adequately document the nature and extent of patient A's pain and its
23 impact on his functioning;
24 (c) failing to adequately document examination findings relevant to patient A's
25 musculoskeletal and neurological condition;
26 (d) failing to adequately document diagnostic testing relevant to the patient's reported
27 chronic pain;

28 / / / /

- 1 (e) failing to adequately document the Respondent's course of treatment for
2 patient A, including patient A's compliance with treatment, progress toward any
3 established treatment goals, and tolerance for prescribed medications; and
4 (f) failing to adequately and accurately document prescribed medication and
5 medication amounts on multiple occasions.

6 75. Respondent committed negligence in his care and treatment of patient B in that he
7 failed to properly evaluate patient B prior to prescribing her buprenorphine for treatment of an
8 opioid use disorder including, but not limited to:

- 9 (a) failing to adequately and independently corroborate patient B's prior diagnosis of
10 an opioid use disorder;
11 (b) failing to adequately address a significant discrepancy in patient B's reported
12 Suboxone use at the outset of buprenorphine treatment;
13 (c) failing to order or review a toxicology drug screen for patient B at the outset of
14 buprenorphine treatment; and
15 (d) failing to review the CURES database for controlled substances listed for
16 patient B at the outset of buprenorphine treatment.

17 76. Respondent committed negligence in his care and treatment of patient B in that he
18 failed to maintain adequate and accurate records pertinent to his prescribing of medications to
19 patient B including, but not limited to:

- 20 (a) failing to adequately document patient B's medical history and relevant physical
21 examination findings;
22 (b) failing to adequately document diagnostic testing for patient B;
23 (c) failing to adequately and accurately document medications and medication
24 amounts prescribed to patient B on multiple occasions;
25 (d) failing to document a treatment plan, patient B's compliance with any such
26 treatment plan, and whether patient B was benefitting or being harmed from
27 treatment;

28 / / / /

- 1 (e) failing to adequately document ancillary treatment rendered to patient B, such as
2 treatment by any consulting specialists; and
3 (f) documenting multiple office visit notes with repetitive and inaccurate content that
4 appears to have been entered by default or copied forward from prior notes.

5 77. Respondent committed negligence in his care and treatment of patient C in that he
6 failed to maintain adequate and accurate records pertaining to Respondent's prescribing of
7 medications to patient C to treat an opioid use disorder including, but not limited to:

- 8 (a) misidentifying patient C's sex in all or nearly all of Respondent's office visit
9 notes for patient C;
10 (b) documenting multiple office visit notes containing repetitive and inaccurate
11 content that appears to have been entered by default or copied forward from prior
12 visit notes;
13 (c) failing to adequately and accurately document the medication or medication
14 amounts prescribed to patient C on multiple occasions;
15 (d) and failing to adequately document the history of patient C's course of treatment
16 with Respondent including, but not limited to, patient C's compliance with
17 treatment, patient C's progress toward treatment goals, and patient C's tolerance
18 for the prescribed medication.

19 **THIRD CAUSE FOR DISCIPLINE**

20 **(Prescribing, Dispensing, or Furnishing of a Dangerous Drug without an Appropriate Prior**
21 **Examination and a Medical Indication)**

22 78. Respondent has further subjected his Physician's and Surgeon's Certificate
23 No. A 36345 to disciplinary action under sections 2227 and 2234, as defined by section 2242, of
24 the Code in that he prescribed, dispensed, or furnished a dangerous drug on one or more
25 occasions without an appropriate prior examination and a medical indication as more particularly
26 alleged in paragraphs 9 to 75, above, which are hereby incorporated by reference and realleged as
27 if fully set forth herein.

28 / / / /

1 **FOURTH CAUSE FOR DISCIPLINE**

2 **(Repeated Acts of Clearly Excessive Prescribing)**

3 79. Respondent has further subjected his Physician's and Surgeon's Certificate
4 No. A 36345 to disciplinary action under sections 2227 and 2234, as defined by section 725, of
5 the Code in that he committed repeated acts of clearly excessive prescribing, furnishing,
6 dispensing or administering of a drug or treatment as more particularly alleged in
7 paragraphs 9 to 75, above, which are hereby incorporated by reference and realleged as if fully set
8 forth herein.

9 **FIFTH CAUSE FOR DISCIPLINE**

10 **(Failure to Maintain Adequate and Accurate Records)**

11 80. Respondent has further subjected his Physician's and Surgeon's Certificate
12 No. A 36345 to disciplinary action under sections 2227 and 2234, as defined by section 2266, of
13 the Code in that he failed to maintain adequate and accurate records relating to his provision of
14 services to one or more patients as more particularly alleged in paragraphs 9 to 77, above, which
15 are hereby incorporated by reference and realleged as if fully set forth herein.

16 **SIXTH CAUSE FOR DISCIPLINE**

17 **(Violation of the Medical Practice Act)**

18 81. Respondent has further subjected his Physician's and Surgeon's Certificate
19 No. A 36345 to disciplinary action under sections 2227 and 2234, as defined by section 2234,
20 subdivision (a), of the Code in that he violated or attempted to violate, directly or indirectly, any
21 provision of the Medical Practice Act as more particularly alleged in paragraphs 9 to 80, above,
22 which are hereby incorporated by reference and realleged as if fully set forth herein.

23 **DISCIPLINARY CONSIDERATIONS**

24 82. To determine the degree of discipline, if any, to be imposed on Respondent,
25 Complainant alleges that on or about May 19, 1998, in a prior action, the Board issued
26 Decision No. 11-96-61601 (the "Decision"), which is hereby incorporated by reference and
27 alleged as if fully set forth herein, wherein the Board found that Respondent committed repeated
28 negligent acts; incompetence, unprofessional conduct, and failed to keep accurate or complete

1 records in rendering medical care and treatment to two pregnant female patients. The decision
2 revoked Respondent's Physician's and Surgeon's Certificate No. A 36345, revocation stayed, and
3 placed Respondent on four years' probation. Probation conditions imposed on Respondent
4 included, but were not limited to, completion of a physician assessment and clinical education
5 program of at least three days and including appropriate patient chart documentation, practice
6 monitoring, and the completion of an ethics course. By a subsequent Board decision on or about
7 March 1, 2001, a Petition for Penalty Relief filed by Respondent was granted and his probation
8 was terminated effective March 30, 2001.

9 **PRAYER**

10 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
11 and that following the hearing, the Medical Board of California issue a decision:

12 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 36345, issued
13 to Respondent Mark Scheier, M.D.;

14 2. Revoking, suspending or denying approval of Respondent Mark Scheier, M.D.'s
15 authority to supervise physician assistants and advanced practice nurses;

16 3. Ordering Respondent Mark Scheier, M.D., if placed on probation, to pay the Board
17 the costs of probation monitoring; and

18 4. Taking such other and further action as deemed necessary and proper.

19
20 DATED: December 31, 2018


21 KIMBERLY KIRCHMEYER
22 Executive Director
23 Medical Board of California
24 Department of Consumer Affairs
25 State of California
26 Complainant
27
28